RetroBC HER2L

• Research type

  Research Study

• Full title

  Retrospective Epidemiology Study. A Multicenter Study to Estimate the Prevalence of HER2-low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice among Unresectable and/or Metastatic Breast Cancer Patients with HER2-low Status – the RetroBC-HER2L Study

• IRAS ID

  297315

• Contact name

  Ciara O'Brien

• Contact email

  ciara.obrien3@nhs.net

• Sponsor organisation

  AstraZeneca

• Duration of Study in the UK

  0 years, 6 months, 2 days

• Research summary

  The aim of this study is to collect data from metastatic Breast Cancer patients previously identified as HER2-neg, regardless of hormone status. This is to describe the the burden, treatment patterns, patient characteristics and clinical outcomes of this disease

• REC name

  London - Surrey Research Ethics Committee

• REC reference

  21/LO/0640

• Date of REC Opinion

  1 Nov 2021

• REC opinion

  Further Information Favourable Opinion